Scope of Sacubitril/Valsartan Eligibility After Heart Failure Hospitalization: Findings From the GWTG-HF Registry (Get With The Guidelines-Heart Failure).

@article{Parikh2017ScopeOS,
  title={Scope of Sacubitril/Valsartan Eligibility After Heart Failure Hospitalization: Findings From the GWTG-HF Registry (Get With The Guidelines-Heart Failure).},
  author={Kishan S. Parikh and Steven J. Lippmann and Melissa A. Greiner and Paul A. Heidenreich and Clyde W. Yancy and Gregg C Fonarow and Adrian F. Hernandez},
  journal={Circulation},
  year={2017},
  volume={135 21},
  pages={2077-2080}
}
May 23, 2017 2077 CORRPONDENCE Sacubitril/valsartan was compared to enalapril in the PARADIGM-HF trial (Prospective Comparison of ARNI [Angiotensin Receptor-Neprilysin Inhibitor] with ACEI [Angiotensin-Converting-Enzyme Inhibitor] to Determine Impact on Global Mortality and Morbidity in Heart Failure [HF]), which was stopped early after an observed 20… CONTINUE READING